147 related articles for article (PubMed ID: 32807051)
1. Strategic Developments & Future Perspective on Gene Therapy for Breast Cancer: Role of mTOR and Brk/ PTK6 as Molecular Targets.
Sahu R; Pattanayak SP
Curr Gene Ther; 2020; 20(4):237-258. PubMed ID: 32807051
[TBL] [Abstract][Full Text] [Related]
2. Tracing the footprints of the breast cancer oncogene BRK - Past till present.
Goel RK; Lukong KE
Biochim Biophys Acta; 2015 Aug; 1856(1):39-54. PubMed ID: 25999240
[TBL] [Abstract][Full Text] [Related]
3. Putting the BRK on breast cancer: From molecular target to therapeutics.
Ang HL; Yuan Y; Lai X; Tan TZ; Wang L; Huang BB; Pandey V; Huang RY; Lobie PE; Goh BC; Sethi G; Yap CT; Chan CW; Lee SC; Kumar AP
Theranostics; 2021; 11(3):1115-1128. PubMed ID: 33391524
[TBL] [Abstract][Full Text] [Related]
4. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
[TBL] [Abstract][Full Text] [Related]
5. Brk/PTK6 signaling in normal and cancer cell models.
Ostrander JH; Daniel AR; Lange CA
Curr Opin Pharmacol; 2010 Dec; 10(6):662-9. PubMed ID: 20832360
[TBL] [Abstract][Full Text] [Related]
6. Impact of protein tyrosine kinase 6 (PTK6) on human epidermal growth factor receptor (HER) signalling in breast cancer.
Ludyga N; Anastasov N; Gonzalez-Vasconcellos I; Ram M; Höfler H; Aubele M
Mol Biosyst; 2011 May; 7(5):1603-12. PubMed ID: 21380407
[TBL] [Abstract][Full Text] [Related]
7. Breast Tumor Kinase (Brk/PTK6) Is Induced by HIF, Glucocorticoid Receptor, and PELP1-Mediated Stress Signaling in Triple-Negative Breast Cancer.
Regan Anderson TM; Ma SH; Raj GV; Cidlowski JA; Helle TM; Knutson TP; Krutilina RI; Seagroves TN; Lange CA
Cancer Res; 2016 Mar; 76(6):1653-63. PubMed ID: 26825173
[TBL] [Abstract][Full Text] [Related]
8. Building a better understanding of the intracellular tyrosine kinase PTK6 - BRK by BRK.
Brauer PM; Tyner AL
Biochim Biophys Acta; 2010 Aug; 1806(1):66-73. PubMed ID: 20193745
[TBL] [Abstract][Full Text] [Related]
9. Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR.
Li X; Lu Y; Liang K; Hsu JM; Albarracin C; Mills GB; Hung MC; Fan Z
Oncogene; 2012 Oct; 31(40):4372-83. PubMed ID: 22231447
[TBL] [Abstract][Full Text] [Related]
10. BRK targets Dok1 for ubiquitin-mediated proteasomal degradation to promote cell proliferation and migration.
Miah S; Goel RK; Dai C; Kalra N; Beaton-Brown E; Bagu ET; Bonham K; Lukong KE
PLoS One; 2014; 9(2):e87684. PubMed ID: 24523872
[TBL] [Abstract][Full Text] [Related]
11. HER2 regulates Brk/PTK6 stability via upregulating calpastatin, an inhibitor of calpain.
Ai M; Qiu S; Lu Y; Fan Z
Cell Signal; 2013 Sep; 25(9):1754-61. PubMed ID: 23707532
[TBL] [Abstract][Full Text] [Related]
12. Cancer-Associated Mutations in Breast Tumor Kinase/PTK6 Differentially Affect Enzyme Activity and Substrate Recognition.
Tsui T; Miller WT
Biochemistry; 2015 May; 54(20):3173-82. PubMed ID: 25940761
[TBL] [Abstract][Full Text] [Related]
13. Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells.
Ostrander JH; Daniel AR; Lofgren K; Kleer CG; Lange CA
Cancer Res; 2007 May; 67(9):4199-209. PubMed ID: 17483331
[TBL] [Abstract][Full Text] [Related]
14. Peruvoside targets apoptosis and autophagy through MAPK Wnt/β-catenin and PI3K/AKT/mTOR signaling pathways in human cancers.
Reddy D; Kumavath R; Tan TZ; Ampasala DR; Kumar AP
Life Sci; 2020 Jan; 241():117147. PubMed ID: 31830480
[TBL] [Abstract][Full Text] [Related]
15. Effects of endoplasmic reticulum stress on the autophagy, apoptosis, and chemotherapy resistance of human breast cancer cells by regulating the PI3K/AKT/mTOR signaling pathway.
Zhong JT; Yu J; Wang HJ; Shi Y; Zhao TS; He BX; Qiao B; Feng ZW
Tumour Biol; 2017 May; 39(5):1010428317697562. PubMed ID: 28459209
[TBL] [Abstract][Full Text] [Related]
16. PTK6/BRK is expressed in the normal mammary gland and activated at the plasma membrane in breast tumors.
Peng M; Emmadi R; Wang Z; Wiley EL; Gann PH; Khan SA; Banerji N; McDonald W; Asztalos S; Pham TN; Tonetti DA; Tyner AL
Oncotarget; 2014 Aug; 5(15):6038-48. PubMed ID: 25153721
[TBL] [Abstract][Full Text] [Related]
17. PTK6 inhibits autophagy to promote uveal melanoma tumorigenesis by binding to SOCS3 and regulating mTOR phosphorylation.
Liu B; Yao X; Zhang C; Liu Y; Wei L; Huang Q; Wang M; Zhang Y; Hu D; Wu W
Cell Death Dis; 2023 Jan; 14(1):55. PubMed ID: 36690663
[TBL] [Abstract][Full Text] [Related]
18. Breast tumor kinase/protein tyrosine kinase 6 (Brk/PTK6) activity in normal and neoplastic biliary epithelia.
Mizuguchi Y; Specht S; Isse K; Sasatomi E; Lunz JG; Takizawa T; Demetris AJ
J Hepatol; 2015 Aug; 63(2):399-407. PubMed ID: 25770659
[TBL] [Abstract][Full Text] [Related]
19. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
Saini KS; Loi S; de Azambuja E; Metzger-Filho O; Saini ML; Ignatiadis M; Dancey JE; Piccart-Gebhart MJ
Cancer Treat Rev; 2013 Dec; 39(8):935-46. PubMed ID: 23643661
[TBL] [Abstract][Full Text] [Related]
20. Small molecule inhibitors reveal PTK6 kinase is not an oncogenic driver in breast cancers.
Qiu L; Levine K; Gajiwala KS; Cronin CN; Nagata A; Johnson E; Kraus M; Tatlock J; Kania R; Foley T; Sun S
PLoS One; 2018; 13(6):e0198374. PubMed ID: 29879184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
